The obese patient. A statistical study and analysis of symptoms, diagnosis and metabolic abnormalities. Sex differences—Treatment

Ray, Henry M.

doi:10.1007/bf03001304

Cited by 18 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The interest in using amphetamines for the purpose of controlling excess body weight was propelled by case reports showing that thrice daily administration of 2 mg desoxyephedrine could decrease body weight by as Anti-Obesity Pharmacotherapies much as 24.5 kg, and seemingly without major adverse effects (Ray, 1947). Nonetheless given their action on the central reward system, amphetamines possess a certain risk for addiction (Schuster and Thompson, 1969;Balster and Schuster, 1973;Yokel and Pickens, 1973;Gotestam and Andersson, 1975).…”

Section: B 24-dinitrophenolmentioning

confidence: 99%

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

et al. 2018

View full text Add to dashboard Cite

Section: B 24-dinitrophenolmentioning

confidence: 99%

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

et al. 2018

View full text Add to dashboard Cite

“…He further suggests weight loss as therapy. Other authors note the frequency of presenting complaints among the obese, concluding that disorders of menstruation and the climacteric are very common (Ray, 1947;Randall, 1947;Rogers, 1964).…”

Section: Clinical Evidencementioning

confidence: 99%

Fat and fertility: Demographic implications of differential fat storage

Huss‐Ashmore

1980

American J Phys Anthropol

View full text Add to dashboard Cite

Anthropologists interested in human nutrition have become intrigued by the possibility of a link between nutritional status, fat stores, and fertility. Frisch (1978) and Frisch and McArthur (1974) have hypothesized such a link, based on studies of body composition at menarche and menstrual dysfunction in anorectics. This review indicates that both over-and undernutrition may interfere with reproductive function, but probably do so only when extreme. Evidence for fat as a regulator of fecundity is conflicting, and is best documented for age at puberty. Effects of fat on birth interval (a demographically more significant parameter) are confounded by the influence of lactation. A review of hormonal and metabolic patterns in obesity and inanation indicate similarities between these conditions and general or psychological stress. It is suggested that fat is better seen as an indicator of systemic function than as a single independent factor. The adaptive value of fat for human populations may lie in its ability to enhance work performance as much as in its influence on fecundity.65

show abstract

“…The main concerns with dexamphetamine relate to toxicity, abuse potential, and concern that the small increase in blood pressure could exacerbate ischemic heart disease ( 16 ). However, amphetamines have been previously studied for the treatment of obesity ( 16 – 19 ) [including in individuals with cardiovascular disease ( 16 )] and also for their psychotropic properties ( 20 ). Griffith et al showed that psychosis can be induced in individuals with no known predisposition within 5 days through dexamphetamine doses of 5–15 mg hourly ( 20 ).…”

Section: Introductionmentioning

confidence: 99%

“…There have been few recent studies that have used amphetamines for treating obesity. In 1947, Ray treated obese patients with racemic amphetamine and methamphetamine and after 8 months achieved weight losses of 12.7 kg in men and 11.0 kg in women ( 19 ). More recently, Levy et al used stimulant medication (mainly amphetamine) in a predominantly female cohort of obese individuals, principally to treat newly diagnosed ADHD ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

Piloting a New Approach to the Treatment of Obesity Using Dexamphetamine

et al. 2015

View full text Add to dashboard Cite

Background and aims: There is a clear need for a new approach to the treatment of obesity, which is inexpensive and is effective for establishing lifestyle change. We conducted a pilot study to evaluate whether dexamphetamine can be used safely, combined with diet and exercise, for treating obesity. Our ultimate aim is to develop a 6-month treatment program for establishing the lifestyle changes necessary for weight control, utilizing dexamphetamine for its psychotropic effect on motivation. We viewed the anorexigenic effect as an additional advantage for promoting initial weight loss.Methods: Obese adults were treated with dexamphetamine for 6 months (maximum of 30 mg twice daily), diet, and exercise. Weight, electrocardiogram, echocardiogram, and blood pressure were monitored.Results: Twelve out of 14 completed 6 months treatment. Weight loss by intention to treat was 10.6 kg (95% CI 5.8–15.5, p < 0.001). The mean weight gain in the 6 months after ceasing dexamphetamine was 4.5 kg (95% CI 1.9–7.2, p = 0.003), leaving a mean weight loss at 12 months from baseline of 7.0 kg (95% CI −13.4 to −0.6, p = 0.03). All reported favorable increases in energy and alertness. Dose-limiting symptoms were mood changes (2) and insomnia (2). None had drug craving on ceasing dexamphetamine, and there were no cardiac complications. Among the seven women, there was a significant correlation for those who lost most weight on treatment to have the least regain in the following 6 months (r = 0.88, p = 0.009).Conclusion: Our treatment with dexamphetamine, diet, and exercise was well tolerated and effective for initial weight loss. Future research will focus on identifying baseline predictive variables associated with long-term weight control.

show abstract

The obese patient. A statistical study and analysis of symptoms, diagnosis and metabolic abnormalities. Sex differences—Treatment

Cited by 18 publications

References 6 publications

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

Fat and fertility: Demographic implications of differential fat storage

Piloting a New Approach to the Treatment of Obesity Using Dexamphetamine

Contact Info

Product

Resources

About